Christine Thöns1, Tina Senff1, Theresa J Hydes2, Angela R Manser3, Falko M Heinemann4, Andreas Heinold4, Martin Heilmann5, Arthur Y Kim6, Markus Uhrberg3, Norbert Scherbaum5, Georg M Lauer7, Salim I Khakoo2, Jörg Timm8. 1. Institute for Virology, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany. 2. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, Hampshire, UK. 3. Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany. 4. Institute for Transfusion Medicine, University of Duisburg-Essen, University Hospital, Essen, Germany. 5. Department for Addiction Medicine and Addictive Behavior, LVR-Hospital Essen, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany. 6. Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 7. Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 8. Institute for Virology, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany. Electronic address: joerg.timm@med.uni-duesseldorf.de.
Abstract
BACKGROUND & AIMS: Natural killer (NK) cell function is regulated by inhibitory and activating receptors including killer cell immunoglobulin-like receptors (KIRs). Here, we analyzed the impact of different KIR/KIR-ligand genotypes on the outcome of hepatitis C virus (HCV) infection in people who inject drugs (PWID). METHODS: KIR/KIR-ligand genotypes associated with spontaneous clearance of HCV infection were identified in a cohort of PWID from Germany (n=266) and further validated in a second anti-HCV positive cohort of PWID recruited in North America (n=342). NK cells of PWID and healthy donors were functionally characterized according to their KIR/KIR-ligand genotype by flow cytometry. RESULTS: Multivariate logistic regression analysis revealed that KIR3DL1/HLA-Bw4 80(T) was associated with spontaneous clearance of HCV infection in PWID, which was confirmed in the PWID cohort from North America. Compared with PWID with detectable HCV RNA, the frequency of individuals with multiple HLA-Bw4 alleles was significantly higher in anti-HCV positive PWID with resolved HCV infection (29.7% vs. 15.2%; p=0.0229) and in anti-HCV seronegative PWID (39.2%; p=0.0006). KIR3DL1+ NK cells from HLA-Bw4 80(T)-positive PWID showed superior functionality compared to HLA-Bw4 80(I)-positive PWID. This differential impact was not observed in healthy donors; however, the HLA-Bw4 copy number strongly correlated with the functionality of KIR3DL1+ NK cells. CONCLUSIONS: HLA-Bw4-80(T) and multiple HLA-Bw4 copies in combination with KIR3DL1 are associated with protection against chronic hepatitis C in PWID by distinct mechanisms. Better licensing of KIR3DL1+ NK cells in the presence of multiple HLA-Bw4 copies is beneficial prior to seroconversion whereas HLA-Bw4 80(T) may be beneficial during acute hepatitis C. Lay summary: Natural killer (NK) cells are part of the innate immune system and are regulated by a complex network of activating and inhibiting receptors. The regulating receptor-ligand pairs of an individual are genetically determined. Here, we identified a particular set of ligand and receptor genes that are associated with better functionality of NK cells and better outcome upon exposure to HCV in a high-risk group.
BACKGROUND & AIMS: Natural killer (NK) cell function is regulated by inhibitory and activating receptors including killer cell immunoglobulin-like receptors (KIRs). Here, we analyzed the impact of different KIR/KIR-ligand genotypes on the outcome of hepatitis C virus (HCV) infection in people who inject drugs (PWID). METHODS:KIR/KIR-ligand genotypes associated with spontaneous clearance of HCV infection were identified in a cohort of PWID from Germany (n=266) and further validated in a second anti-HCV positive cohort of PWID recruited in North America (n=342). NK cells of PWID and healthy donors were functionally characterized according to their KIR/KIR-ligand genotype by flow cytometry. RESULTS: Multivariate logistic regression analysis revealed that KIR3DL1/HLA-Bw4 80(T) was associated with spontaneous clearance of HCV infection in PWID, which was confirmed in the PWID cohort from North America. Compared with PWID with detectable HCV RNA, the frequency of individuals with multiple HLA-Bw4 alleles was significantly higher in anti-HCV positive PWID with resolved HCV infection (29.7% vs. 15.2%; p=0.0229) and in anti-HCV seronegative PWID (39.2%; p=0.0006). KIR3DL1+ NK cells from HLA-Bw4 80(T)-positive PWID showed superior functionality compared to HLA-Bw4 80(I)-positive PWID. This differential impact was not observed in healthy donors; however, the HLA-Bw4 copy number strongly correlated with the functionality of KIR3DL1+ NK cells. CONCLUSIONS: HLA-Bw4-80(T) and multiple HLA-Bw4 copies in combination with KIR3DL1 are associated with protection against chronic hepatitis C in PWID by distinct mechanisms. Better licensing of KIR3DL1+ NK cells in the presence of multiple HLA-Bw4 copies is beneficial prior to seroconversion whereas HLA-Bw4 80(T) may be beneficial during acute hepatitis C. Lay summary: Natural killer (NK) cells are part of the innate immune system and are regulated by a complex network of activating and inhibiting receptors. The regulating receptor-ligand pairs of an individual are genetically determined. Here, we identified a particular set of ligand and receptor genes that are associated with better functionality of NK cells and better outcome upon exposure to HCV in a high-risk group.
Authors: Anfei Huang; Prashant V Shinde; Jun Huang; Tina Senff; Haifeng C Xu; Cassandra Margotta; Dieter Häussinger; Thomas E Willnow; Jinping Zhang; Aleksandra A Pandyra; Jörg Timm; Sascha Weggen; Karl S Lang; Philipp A Lang Journal: JCI Insight Date: 2019-09-05
Authors: Johannes Schetelig; Henning Baldauf; Falk Heidenreich; Carolin Massalski; Sandra Frank; Jürgen Sauter; Matthias Stelljes; Francis Ayuketang Ayuk; Wolfgang A Bethge; Gesine Bug; Stefan Klein; Sarah Wendler; Vinzenz Lange; Liesbeth C de Wreede; Daniel Fürst; Guido Kobbe; Hellmut D Ottinger; Dietrich W Beelen; Joannis Mytilineos; Katharina Fleischhauer; Alexander H Schmidt; Martin Bornhäuser Journal: Blood Date: 2020-04-16 Impact factor: 22.113
Authors: Kattria van der Ploeg; Jean-Benoît Le Luduec; Philip A Stevenson; Soo Park; Ted A Gooley; Effie W Petersdorf; Brian C Shaffer; Katharine C Hsu Journal: Blood Adv Date: 2020-10-13
Authors: Paula Martínez-Román; Celia Crespo-Bermejo; Daniel Valle-Millares; Violeta Lara-Aguilar; Sonia Arca-Lafuente; Luz Martín-Carbonero; Pablo Ryan; Ignacio de Los Santos; María Rosa López-Huertas; Claudia Palladino; María Muñoz-Muñoz; Amanda Fernández-Rodríguez; Mayte Coiras; Verónica Briz Journal: J Clin Med Date: 2022-06-21 Impact factor: 4.964
Authors: N Legrand; G David; C Retière; C Allavena; A Rodallec; A Gaultier; D Salmon; A Cesbron; L Wittkop; F Raffi; K Gendzekhadze; K Gagne Journal: Clin Exp Immunol Date: 2021-02-02 Impact factor: 5.732
Authors: Louis-Marie Yindom; Maimuna Mendy; Christopher Bodimeade; Caroline Chambion; Peter Aka; Hilton C Whittle; Sarah L Rowland-Jones; Robert Walton Journal: PLoS One Date: 2017-11-17 Impact factor: 3.240